JP2019513804A - 治療用化合物 - Google Patents

治療用化合物 Download PDF

Info

Publication number
JP2019513804A
JP2019513804A JP2018554572A JP2018554572A JP2019513804A JP 2019513804 A JP2019513804 A JP 2019513804A JP 2018554572 A JP2018554572 A JP 2018554572A JP 2018554572 A JP2018554572 A JP 2018554572A JP 2019513804 A JP2019513804 A JP 2019513804A
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018554572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513804A5 (https=
Inventor
ジェイ． ベネット，マイケル
ジェイ． ベネット，マイケル
エム． べタンコート，フアン
エム． べタンコート，フアン
ボロアー，アモフ
エー． カノウニ，トウフィケ
エー． カノウニ，トウフィケ
エー． スタッフォード，ジェフリー
エー． スタッフォード，ジェフリー
エム． ヴィール，ジェームス
エム． ヴィール，ジェームス
ビー． ウォレス，マイケル
ビー． ウォレス，マイケル
Original Assignee
セルジーン クオンティセル リサーチ，インク．
セルジーン クオンティセル リサーチ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルジーン クオンティセル リサーチ，インク．, セルジーン クオンティセル リサーチ，インク． filed Critical セルジーン クオンティセル リサーチ，インク．
Publication of JP2019513804A publication Critical patent/JP2019513804A/ja
Publication of JP2019513804A5 publication Critical patent/JP2019513804A5/ja
Priority to JP2022013404A priority Critical patent/JP2022064967A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2018554572A 2016-04-18 2017-04-14 治療用化合物 Pending JP2019513804A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022013404A JP2022064967A (ja) 2016-04-18 2022-01-31 治療用化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324279P 2016-04-18 2016-04-18
US62/324,279 2016-04-18
PCT/US2017/027815 WO2017184462A1 (en) 2016-04-18 2017-04-14 Therapeutic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022013404A Division JP2022064967A (ja) 2016-04-18 2022-01-31 治療用化合物

Publications (2)

Publication Number Publication Date
JP2019513804A true JP2019513804A (ja) 2019-05-30
JP2019513804A5 JP2019513804A5 (https=) 2020-05-21

Family

ID=60039979

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018554572A Pending JP2019513804A (ja) 2016-04-18 2017-04-14 治療用化合物
JP2022013404A Pending JP2022064967A (ja) 2016-04-18 2022-01-31 治療用化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022013404A Pending JP2022064967A (ja) 2016-04-18 2022-01-31 治療用化合物

Country Status (7)

Country Link
US (1) US10202360B2 (https=)
EP (1) EP3445750A4 (https=)
JP (2) JP2019513804A (https=)
AR (1) AR108223A1 (https=)
AU (1) AU2017252276A1 (https=)
TW (1) TW201739744A (https=)
WO (1) WO2017184462A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11890275B2 (en) 2017-04-18 2024-02-06 Celgene Quanticel Research, Inc. Therapeutic compounds

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110016014B (zh) * 2018-01-08 2023-02-17 中国科学院上海药物研究所 Ezh2抑制剂及其制备和抗肿瘤治疗中的应用
AU2019245403B2 (en) 2018-03-29 2025-02-06 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
EP3997070A4 (en) 2019-07-02 2023-07-26 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
EP4143166A4 (en) * 2020-04-29 2024-10-30 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
SMT202500271T1 (it) 2020-07-02 2025-09-12 Incyte Corp Composti di urea triciclici come inibitori di v617f di jak2
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022072648A1 (en) 2020-10-02 2022-04-07 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
JP7777131B2 (ja) 2020-10-02 2025-11-27 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
CN112225738B (zh) * 2020-12-18 2021-04-13 北京鑫开元医药科技有限公司 作为tlr8激动剂的化合物、其制备方法、组合物及其用途
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
CN115703760B (zh) * 2021-08-11 2024-05-31 山东大学 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用
FI4426434T3 (fi) 2021-11-02 2025-11-24 Flare Therapeutics Inc Pparg:n käänteisagonisteja ja niiden käyttöjä
CN119173514A (zh) 2022-03-17 2024-12-20 因赛特公司 作为jak2 v617f抑制剂的三环脲化合物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
WO2008150446A1 (en) * 2007-05-30 2008-12-11 Congxin Liang Inhibitors of protein kinases
WO2012020786A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
WO2012101654A2 (en) * 2011-01-25 2012-08-02 Sphaera Pharma Pvt. Ltd Novel triazine compounds
WO2013180183A1 (ja) * 2012-05-30 2013-12-05 日本新薬株式会社 芳香族複素環誘導体及び医薬
WO2014177524A1 (en) * 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
WO2015058160A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2011970A1 (en) 1970-03-13 1971-11-18 CH. Boehringer Sohn, 6507 Ingelheim Imidazo-(1, 2-a)- pyrimidines prepn
US3635667A (en) 1970-07-23 1972-01-18 Fmc Corp Drycleaning with hydrogen peroxide
BE786028A (fr) 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2356005A1 (de) 1973-11-09 1975-05-22 Boehringer Sohn Ingelheim Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung
AU577105B2 (en) 1985-04-02 1988-09-15 T.P.O. :Pharmachim: Acylaminic penicillin derivatives
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
BR0314759A (pt) 2002-09-26 2005-07-26 Pfizer Derivados de pirazol
JP2005089352A (ja) 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
WO2005030791A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
KR100703068B1 (ko) 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
CN1938296A (zh) 2004-04-01 2007-03-28 安斯泰来制药有限公司 作为腺苷拮抗剂的吡嗪衍生物及其制药用途
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR100781704B1 (ko) 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
KR101373535B1 (ko) 2005-07-26 2014-03-12 사노피 Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체
JP5049970B2 (ja) 2005-07-26 2012-10-17 サノフイ Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
US20070099911A1 (en) 2005-10-28 2007-05-03 Wyeth Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
RU2455302C2 (ru) 2006-12-27 2012-07-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
RU2468011C2 (ru) 2006-12-27 2012-11-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолина и изохинолинона
WO2009029214A1 (en) 2007-08-23 2009-03-05 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
MX2010008375A (es) 2008-01-30 2011-03-04 Cephalon Inc Star Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
JP5433691B2 (ja) 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
HRP20160967T1 (hr) 2009-10-06 2016-10-07 Millennium Pharmaceuticals, Inc. Heterociklički spojevi korisni kao pdk1 inhibitori
JP5826261B2 (ja) 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌に対する使用のためのキナーゼ阻害剤としての２，４−ジアリール置換［１，８］ナフチリジン
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
CN103183675A (zh) 2011-12-27 2013-07-03 山东轩竹医药科技有限公司 磷酸二酯酶-4抑制剂
US9321764B2 (en) * 2013-03-12 2016-04-26 Abbvie Inc. Dihydro-pyrrolopyridinone inhibitors
WO2014140077A1 (en) * 2013-03-14 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Furopyridines as bromodomain inhibitors
MY190835A (en) * 2014-01-09 2022-05-12 Orion Corp Bicyclic heterrocyclic derivatives as bromodomain inhibitors
CN106794181A (zh) * 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
EP3484854B1 (en) * 2016-07-18 2021-01-20 National Institute Of Biological Sciences, Beijing Apoptosis inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
WO2008150446A1 (en) * 2007-05-30 2008-12-11 Congxin Liang Inhibitors of protein kinases
WO2012020786A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
WO2012101654A2 (en) * 2011-01-25 2012-08-02 Sphaera Pharma Pvt. Ltd Novel triazine compounds
WO2013180183A1 (ja) * 2012-05-30 2013-12-05 日本新薬株式会社 芳香族複素環誘導体及び医薬
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
WO2014177524A1 (en) * 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
WO2015058160A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＢＩＯＯＲＧＡＮＩＣ ＆ ＭＥＤＩＣＩＮＡＬ ＣＨＥＭＩＳＴＲＹ ＬＥＴＴＥＲＳ, vol. 21, no. 1, JPN6021010998, 2011, pages 66 - 75, ISSN: 0004628583 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11890275B2 (en) 2017-04-18 2024-02-06 Celgene Quanticel Research, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
EP3445750A1 (en) 2019-02-27
AU2017252276A1 (en) 2018-11-15
JP2022064967A (ja) 2022-04-26
WO2017184462A1 (en) 2017-10-26
AR108223A1 (es) 2018-08-01
US20170298040A1 (en) 2017-10-19
US10202360B2 (en) 2019-02-12
EP3445750A4 (en) 2019-11-27
TW201739744A (zh) 2017-11-16

Similar Documents

Publication Publication Date Title
JP2019513804A (ja) 治療用化合物
JP6734896B2 (ja) ブロモドメイン阻害剤
CN111423416B (zh) Ret的抑制剂
KR101614572B1 (ko) 디아미노 헤테로환 카르복사미드 화합물
CN102892759B (zh) 具有犬尿氨酸产生抑制作用的含氮杂环化合物
US11890275B2 (en) Therapeutic compounds
EP3737683A1 (en) Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
AU2022262335A1 (en) Compounds as pd1/pd-l1 inhibitors and methods thereof
JP4834441B2 (ja) ピリミジニルアルキルチオ基を有する新規環式化合物
AU2020299632A1 (en) Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200409

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211101